153 related articles for article (PubMed ID: 15150550)
1. Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer.
Toi M; Bando H; Horiguchi S; Takada M; Kataoka A; Ueno T; Saji S; Muta M; Funata N; Ohno S
Br J Cancer; 2004 Jun; 90(12):2338-43. PubMed ID: 15150550
[TBL] [Abstract][Full Text] [Related]
2. Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer.
Puglisi F; Cardellino GG; Crivellari D; Di Loreto C; Magri MD; Minisini AM; Mansutti M; Andreetta C; Russo S; Lombardi D; Perin T; Damante G; Veronesi A
Ann Oncol; 2008 Sep; 19(9):1541-6. PubMed ID: 18441329
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
[TBL] [Abstract][Full Text] [Related]
4. A phase II trial of capecitabine and docetaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide (FEC) as preoperative treatment in women with stage II/III breast cancer.
Jinno H; Sakata M; Hayashida T; Takahashi M; Mukai M; Ikeda T; Kitagawa Y
Ann Oncol; 2010 Jun; 21(6):1262-1266. PubMed ID: 19854722
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant docetaxel and capecitabine and the use of thymidine phosphorylase as a predictive biomarker in breast cancer.
Layman RM; Thomas DG; Griffith KA; Smerage JB; Helvie MA; Roubidoux MA; Diehl KM; Newman LA; Sabel MS; Hayman JA; Pierce LJ; Hayes DF; Schott AF
Clin Cancer Res; 2007 Jul; 13(14):4092-7. PubMed ID: 17634534
[TBL] [Abstract][Full Text] [Related]
6. Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil– epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy.
Ohno S; Chow LW; Sato N; Masuda N; Sasano H; Takahashi F; Bando H; Iwata H; Morimoto T; Kamigaki S; Nakayama T; Nakamura S; Kuroi K; Aogi K; Kashiwaba M; Yamashita H; Hisamatsu K; Ito Y; Yamamoto Y; Ueno T; Fakhrejahani E; Yoshida N; Toi M
Breast Cancer Res Treat; 2013 Nov; 142(1):69-80. PubMed ID: 24122389
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant 5-fluorouracil, epirubicin and cyclophosphamide chemotherapy followed by docetaxel in refractory patients with locally advanced breast cancer.
Heller W; Mazhar D; Ward R; Sinnett HD; Lowdell C; Phillips R; Shousha S; Fayaz A; Palmieri C; Coombes RC
Oncol Rep; 2007 Jan; 17(1):253-9. PubMed ID: 17143506
[TBL] [Abstract][Full Text] [Related]
8. Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial.
Bonnefoi H; Potti A; Delorenzi M; Mauriac L; Campone M; Tubiana-Hulin M; Petit T; Rouanet P; Jassem J; Blot E; Becette V; Farmer P; André S; Acharya CR; Mukherjee S; Cameron D; Bergh J; Nevins JR; Iggo RD
Lancet Oncol; 2007 Dec; 8(12):1071-1078. PubMed ID: 18024211
[TBL] [Abstract][Full Text] [Related]
9. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study.
von Minckwitz G; Rezai M; Loibl S; Fasching PA; Huober J; Tesch H; Bauerfeind I; Hilfrich J; Eidtmann H; Gerber B; Hanusch C; Kühn T; du Bois A; Blohmer JU; Thomssen C; Dan Costa S; Jackisch C; Kaufmann M; Mehta K; Untch M
J Clin Oncol; 2010 Apr; 28(12):2015-23. PubMed ID: 20308671
[TBL] [Abstract][Full Text] [Related]
10. Capecitabine plus docetaxel combination chemotherapy for metastatic breast cancer.
Saeki T; Takashima S
Breast Cancer; 2004; 11(2):116-20. PubMed ID: 15550855
[TBL] [Abstract][Full Text] [Related]
11. Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro).
von Minckwitz G; Rezai M; Fasching PA; Huober J; Tesch H; Bauerfeind I; Hilfrich J; Eidtmann H; Gerber B; Hanusch C; Blohmer JU; Costa SD; Jackisch C; Paepke S; Schneeweiss A; Kümmel S; Denkert C; Mehta K; Loibl S; Untch M
Ann Oncol; 2014 Jan; 25(1):81-9. PubMed ID: 24273046
[TBL] [Abstract][Full Text] [Related]
12. Thymidine phosphorylase expression in tumour cells and tumour response to capecitabine plus docetaxel chemotherapy in non-small cell lung cancer.
Han JY; Hong EK; Lee SY; Yoon SM; Lee DH; Lee JS
J Clin Pathol; 2005 Jun; 58(6):650-4. PubMed ID: 15917420
[TBL] [Abstract][Full Text] [Related]
13. Taxane-based chemotherapy enhances response to neoadjuvant treatment for stage II and III breast cancer.
Andrade JM; Carrara HH; Pimentel FF; Marana HR; Macchetti AH; Mouro LR; Zola FE; Tiezzi DG
Med Oncol; 2011 Dec; 28 Suppl 1():S65-9. PubMed ID: 20953738
[TBL] [Abstract][Full Text] [Related]
14. 5-Fluorouracil, adriamycin, cyclophosphamide (FAC) vs. 5-fluorouracil, epirubicin, cyclophosphamide (FEC) in metastatic breast cancer.
Lopez M; Papaldo P; Di Lauro L; Vici P; Carpano S; Conti EM
Oncology; 1989; 46(1):1-5. PubMed ID: 2915887
[TBL] [Abstract][Full Text] [Related]
15. Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study.
Martín M; Ruiz Simón A; Ruiz Borrego M; Ribelles N; Rodríguez-Lescure Á; Muñoz-Mateu M; González S; Margelí Vila M; Barnadas A; Ramos M; Del Barco Berron S; Jara C; Calvo L; Martínez-Jáñez N; Mendiola Fernández C; Rodríguez CA; Martínez de Dueñas E; Andrés R; Plazaola A; de la Haba-Rodríguez J; López-Vega JM; Adrover E; Ballesteros AI; Santaballa A; Sánchez-Rovira P; Baena-Cañada JM; Casas M; del Carmen Cámara M; Carrasco EM; Lluch A
J Clin Oncol; 2015 Nov; 33(32):3788-95. PubMed ID: 26416999
[TBL] [Abstract][Full Text] [Related]
16. Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG).
Mavroudis D; Matikas A; Malamos N; Papakotoulas P; Kakolyris S; Boukovinas I; Athanasiadis A; Kentepozidis N; Ziras N; Katsaounis P; Saloustros E; Georgoulias V;
Ann Oncol; 2016 Oct; 27(10):1873-8. PubMed ID: 27502729
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Kokko R; Ahlgren J; Auvinen P; Paija O; Helle L; Villman K; Nyandoto P; Nilsson G; Pajunen M; Asola R; Poikonen P; Leinonen M; Kataja V; Bono P; Lindman H
J Clin Oncol; 2012 Jan; 30(1):11-8. PubMed ID: 22105826
[TBL] [Abstract][Full Text] [Related]
18. A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer.
Ishiguro H; Masuda N; Sato N; Higaki K; Morimoto T; Yanagita Y; Mizutani M; Ohtani S; Kaneko K; Fujisawa T; Takahashi M; Kadoya T; Matsunami N; Yamamoto Y; Ohno S; Takano T; Morita S; Tanaka-Mizuno S; Toi M
Breast Cancer Res Treat; 2020 Apr; 180(3):715-724. PubMed ID: 32170634
[TBL] [Abstract][Full Text] [Related]
19. Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.
Rastogi P; Buyse ME; Swain SM; Jacobs SA; Robidoux A; Liepman MK; Pajon ER; Dy PA; Posada JG; Melnik MK; Piette F; Geyer CE; Mamounas EP; Wolmark N
Clin Breast Cancer; 2011 Aug; 11(4):228-34. PubMed ID: 21684812
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial.
Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Asola R; Kokko R; Ahlgren J; Auvinen P; Hemminki A; Paija O; Helle L; Nuortio L; Villman K; Nilsson G; Lahtela SL; Lehtiö K; Pajunen M; Poikonen P; Nyandoto P; Kataja V; Bono P; Leinonen M; Lindman H;
Lancet Oncol; 2009 Dec; 10(12):1145-51. PubMed ID: 19906561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]